Skip to main content
Top
Published in: BMC Nephrology 1/2022

Open Access 01-12-2022 | Human Immunodeficiency Virus | Research

Incidence of impaired kidney function among people with HIV: a systematic review and meta-analysis

Authors: Ruizi Shi, Xiaoxiao Chen, Haijiang Lin, Yingying Ding, Na He

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Background

In the era of combination antiretroviral therapy (ART), the incidence, manifestations and severity of kidney diseases have dramatically changed in people living with HIV (PLWH). Little is known about the incidence of impaired kidney function (IKF) measured by serum creatine-based estimated glomerular filtration rate (eGFR) in PLWH.

Methods

In this systematic review and meta-analysis, we searched PubMed, Ovid, Medline, Embase and Web of Science for studies published before May 7th, 2021, with estimates of incidence of IKF among PLWH. We independently reviewed each study for quality by using the Newcastle-Ottawa scale. The incidence and 95% confidence intervals (CIs) were calculated using random-effects model.

Results

Sixty out of 3797 identifiable studies were eligible for the meta-analysis. A total of 19 definitions of IKF were described and categorized into three types: the threshold of eGFR, an absolute or percent decrease in eGFR, and certain eGFR threshold combined with decrement in eGFR. The eGFR< 60 ml/min/1.73m2 was the most widely used definition or criterion for IKF, by which the pooled incidence rate of IKF was 12.50 (95%CI: 9.00–17.36) per 1000 person years (PYs). The second most-studied outcome was a > 25% decrease in eGFR, followed by eGFR< 90 ml/min/1.73m2, eGFR< 30 ml/min/1.73m2 and a combination of eGFR threshold plus decreased eGFR. The reported incidence rates of IKF differ widely by different definitions of IKF. The highest pooled incidence was observed for those with > 25% decrease in eGFR, while the lowest was observed in those with eGFR < 30 ml/min/1.73m2. Substantial heterogeneity was identified across most estimates.

Conclusion

Our study provides a comprehensive summary of eGFR-based definitions and incidence rates of IKF in PLWH, not only promoting our understanding of IKF, but also underscoring needs for a concerted action to unify definitions and outcomes of IKF and their applications in AIDS care.
Appendix
Available only for authorised users
Literature
2.
go back to reference Bärnighausen T. The HIV treatment cascade and antiretroviral impact in different populations. Curr Opin HIV AIDS. 2015;10(6):391–4.PubMed Bärnighausen T. The HIV treatment cascade and antiretroviral impact in different populations. Curr Opin HIV AIDS. 2015;10(6):391–4.PubMed
3.
go back to reference Estimates of global, Regional, and national incidence, prevalence, and mortality of HIV, 1980-2015. The global burden of disease study 2015. Lancet HIV. 2016;3(8):e361–87.CrossRef Estimates of global, Regional, and national incidence, prevalence, and mortality of HIV, 1980-2015. The global burden of disease study 2015. Lancet HIV. 2016;3(8):e361–87.CrossRef
5.
go back to reference Kimmel PL, Barisoni L, Kopp JB. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann Intern Med. 2003;139(3):214–26.PubMedCrossRef Kimmel PL, Barisoni L, Kopp JB. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann Intern Med. 2003;139(3):214–26.PubMedCrossRef
6.
go back to reference Collaboration GCKD. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709–33.CrossRef Collaboration GCKD. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709–33.CrossRef
7.
go back to reference Rosenberg AZ, Naicker S, Winkler CA, Kopp JB. HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nat Rev Nephrol. 2015;11(3):150–60.PubMedCrossRef Rosenberg AZ, Naicker S, Winkler CA, Kopp JB. HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nat Rev Nephrol. 2015;11(3):150–60.PubMedCrossRef
8.
go back to reference Nobakht E, Cohen SD, Rosenberg AZ, Kimmel PL. HIV-associated immune complex kidney disease. Nat Rev Nephrol. 2016;12(5):291–300.PubMedCrossRef Nobakht E, Cohen SD, Rosenberg AZ, Kimmel PL. HIV-associated immune complex kidney disease. Nat Rev Nephrol. 2016;12(5):291–300.PubMedCrossRef
9.
go back to reference Cohen SD, Kopp JB, Kimmel PL. Kidney diseases associated with human immunodeficiency virus infection. N Engl J Med. 2017;377(24):2363–74.PubMedCrossRef Cohen SD, Kopp JB, Kimmel PL. Kidney diseases associated with human immunodeficiency virus infection. N Engl J Med. 2017;377(24):2363–74.PubMedCrossRef
10.
go back to reference Swanepoel CR, Atta MG, D'Agati VD, Estrella MM, Fogo AB, Naicker S, et al. Kidney disease in the setting of HIV infection: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2018;93(3):545–59.PubMedPubMedCentralCrossRef Swanepoel CR, Atta MG, D'Agati VD, Estrella MM, Fogo AB, Naicker S, et al. Kidney disease in the setting of HIV infection: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2018;93(3):545–59.PubMedPubMedCentralCrossRef
11.
go back to reference Kudose S, Santoriello D, Bomback AS, Stokes MB, Batal I, Markowitz GS, et al. The spectrum of kidney biopsy findings in HIV-infected patients in the modern era. Kidney Int. 2020;97(5):1006–16.PubMedCrossRef Kudose S, Santoriello D, Bomback AS, Stokes MB, Batal I, Markowitz GS, et al. The spectrum of kidney biopsy findings in HIV-infected patients in the modern era. Kidney Int. 2020;97(5):1006–16.PubMedCrossRef
12.
go back to reference George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS. 2010;24(3):387–94.PubMedCrossRef George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS. 2010;24(3):387–94.PubMedCrossRef
13.
go back to reference Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA. Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. Am J Kidney Dis. 2012;60(4):539–47.PubMedPubMedCentralCrossRef Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA. Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. Am J Kidney Dis. 2012;60(4):539–47.PubMedPubMedCentralCrossRef
14.
go back to reference Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.
15.
go back to reference Inker LA, Wyatt C, Creamer R, Hellinger J, Hotta M, Leppo M, et al. Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals. J Acquir Immune Defic Syndr. 2012;61(3):302–9.PubMedPubMedCentralCrossRef Inker LA, Wyatt C, Creamer R, Hellinger J, Hotta M, Leppo M, et al. Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals. J Acquir Immune Defic Syndr. 2012;61(3):302–9.PubMedPubMedCentralCrossRef
16.
go back to reference Ekrikpo UE, Kengne AP, Bello AK, Effa EE, Noubiap JJ, Salako BL, et al. Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis. PLoS One. 2018;13(4). Ekrikpo UE, Kengne AP, Bello AK, Effa EE, Noubiap JJ, Salako BL, et al. Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis. PLoS One. 2018;13(4).
17.
go back to reference IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14(1):25.PubMedPubMedCentralCrossRef IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14(1):25.PubMedPubMedCentralCrossRef
18.
go back to reference Lucas GM, Clarke W, Kagaayi J, Atta MG, Fine DM, Laeyendecker O, et al. Decreased kidney function in a community-based cohort of HIV-infected and HIV-negative individuals in Rakai, Uganda. J Acquir Immune Defic Syndr Hum Retrovirol. 2010;55(4):491–4.CrossRef Lucas GM, Clarke W, Kagaayi J, Atta MG, Fine DM, Laeyendecker O, et al. Decreased kidney function in a community-based cohort of HIV-infected and HIV-negative individuals in Rakai, Uganda. J Acquir Immune Defic Syndr Hum Retrovirol. 2010;55(4):491–4.CrossRef
19.
go back to reference Monteagudo-Chu MO, Chang MH, Fung HB, Brau N. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients. J Pharm Pract. 2012;25(5):552–9.PubMedCrossRef Monteagudo-Chu MO, Chang MH, Fung HB, Brau N. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients. J Pharm Pract. 2012;25(5):552–9.PubMedCrossRef
20.
go back to reference Laprise C, Baril JG, Dufresne S, Trottier H. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis. 2013;56(4):567–75.PubMedCrossRef Laprise C, Baril JG, Dufresne S, Trottier H. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis. 2013;56(4):567–75.PubMedCrossRef
21.
go back to reference Mapesi H, Kalinjuma AV, Ngerecha A, Franzeck F, Hatz C, Tanner M, et al. Prevalence and evolution of renal impairment in people living with HIV in rural Tanzania. Open Forum Infect Dis. 2018;5(4):ofy072.PubMedPubMedCentralCrossRef Mapesi H, Kalinjuma AV, Ngerecha A, Franzeck F, Hatz C, Tanner M, et al. Prevalence and evolution of renal impairment in people living with HIV in rural Tanzania. Open Forum Infect Dis. 2018;5(4):ofy072.PubMedPubMedCentralCrossRef
22.
go back to reference Ding Y, Duan S, Ye R, Yao S, Cao D, Yang Y, et al. Effects of aging, baseline renal function and stage of HIV infection on post-treatment changes in renal function among HIV-infected patients: a retrospective cohort study. HIV Med. 2019;20(9):591–600.PubMedCrossRef Ding Y, Duan S, Ye R, Yao S, Cao D, Yang Y, et al. Effects of aging, baseline renal function and stage of HIV infection on post-treatment changes in renal function among HIV-infected patients: a retrospective cohort study. HIV Med. 2019;20(9):591–600.PubMedCrossRef
23.
go back to reference Liu F, Xu A, Zhao H, Yang Z, Chen C, Ranieri B, et al. Longitudinal progression of estimated GFR in HIV-1-infected patients with normal renal function on tenofovir-based therapy in China. Ther Clin Risk Manag. 2020;16:299–310.PubMedPubMedCentralCrossRef Liu F, Xu A, Zhao H, Yang Z, Chen C, Ranieri B, et al. Longitudinal progression of estimated GFR in HIV-1-infected patients with normal renal function on tenofovir-based therapy in China. Ther Clin Risk Manag. 2020;16:299–310.PubMedPubMedCentralCrossRef
24.
go back to reference Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867–75.PubMedCrossRef Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867–75.PubMedCrossRef
25.
go back to reference Zachor H, Machekano R, Estrella MM, Veldkamp PJ, Zeier MD, Uthman OA, et al. Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens. AIDS. 2016;30(8):1221–8.PubMedCrossRef Zachor H, Machekano R, Estrella MM, Veldkamp PJ, Zeier MD, Uthman OA, et al. Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens. AIDS. 2016;30(8):1221–8.PubMedCrossRef
26.
go back to reference Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, Moore RD. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis. 2008;197(11):1548–57.PubMedCrossRef Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, Moore RD. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis. 2008;197(11):1548–57.PubMedCrossRef
27.
go back to reference Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10(6):329–36.PubMedCrossRef Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10(6):329–36.PubMedCrossRef
28.
go back to reference Flandre P, Pugliese P, Cuzin L, Bagnis CI, Tack I, Cabie A, et al. Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol. 2011;6(7):1700–7.PubMedCrossRef Flandre P, Pugliese P, Cuzin L, Bagnis CI, Tack I, Cabie A, et al. Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol. 2011;6(7):1700–7.PubMedCrossRef
29.
go back to reference Rasch MG, Engsig FN, Feldt-Rasmussen B, Kirk O, Kronborg G, Pedersen C, et al. Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study. Scand J Infect Dis. 2012;44(9):689–96.PubMedCrossRef Rasch MG, Engsig FN, Feldt-Rasmussen B, Kirk O, Kronborg G, Pedersen C, et al. Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study. Scand J Infect Dis. 2012;44(9):689–96.PubMedCrossRef
30.
go back to reference Rockwood N, Mandalia S, Sirsokosta J, Gazzard B, Nelson M. A comparative analysis of risk factors associated with renal impairment and highly active antiretroviral therapy. J Antivir Antiretrovir. 2012;4(2):21–5.CrossRef Rockwood N, Mandalia S, Sirsokosta J, Gazzard B, Nelson M. A comparative analysis of risk factors associated with renal impairment and highly active antiretroviral therapy. J Antivir Antiretrovir. 2012;4(2):21–5.CrossRef
31.
go back to reference Kalayjian RC, Lau B, Mechekano RN, Crane HM, Rodriguez B, Salata RA, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS. 2012;26(15):1907–15.PubMedCrossRef Kalayjian RC, Lau B, Mechekano RN, Crane HM, Rodriguez B, Salata RA, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS. 2012;26(15):1907–15.PubMedCrossRef
32.
go back to reference Ganesan A, Krantz EM, Hullsiek KH, Riddle MS, Weintrob AC, Lalani T, et al. Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care. HIV Med. 2013;14(2):65–76.PubMedCrossRef Ganesan A, Krantz EM, Hullsiek KH, Riddle MS, Weintrob AC, Lalani T, et al. Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care. HIV Med. 2013;14(2):65–76.PubMedCrossRef
33.
go back to reference Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Déti E, et al. 【危险因素-诸多】role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012. PLoS One. 2013;8(6):e66223.PubMedPubMedCentralCrossRef Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Déti E, et al. 【危险因素-诸多】role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012. PLoS One. 2013;8(6):e66223.PubMedPubMedCentralCrossRef
34.
go back to reference Lucas GM, Jing Y, Sulkowski M, Abraham AG, Estrella MM, Atta MG, et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis. 2013;208(8):1240–9.PubMedPubMedCentralCrossRef Lucas GM, Jing Y, Sulkowski M, Abraham AG, Estrella MM, Atta MG, et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis. 2013;208(8):1240–9.PubMedPubMedCentralCrossRef
35.
go back to reference Scherzer R, Gandhi M, Estrella MM, Tien PC, Deeks SG, Grunfeld C, et al. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans. AIDS. 2014;28(9):1289–95.PubMedCrossRef Scherzer R, Gandhi M, Estrella MM, Tien PC, Deeks SG, Grunfeld C, et al. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans. AIDS. 2014;28(9):1289–95.PubMedCrossRef
36.
go back to reference Pujari SN, Smith C, Makane A, Youle M, Johnson M, Bele V, et al. Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom. BMC Infect Dis. 2014;14:173.PubMedPubMedCentralCrossRef Pujari SN, Smith C, Makane A, Youle M, Johnson M, Bele V, et al. Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom. BMC Infect Dis. 2014;14:173.PubMedPubMedCentralCrossRef
37.
go back to reference Nishijima T, Kawasaki Y, Tanaka N, Mizushima D, Aoki T, Watanabe K, et al. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS. 2014;28(13):1903–10.PubMedCrossRef Nishijima T, Kawasaki Y, Tanaka N, Mizushima D, Aoki T, Watanabe K, et al. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS. 2014;28(13):1903–10.PubMedCrossRef
38.
go back to reference Quesada PR, Esteban LL, Garcia JR, Sanchez RV, Garcia TM, Alonso-Vega GG, et al. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. Int J Clin Pharm. 2015;37(5):865–72.PubMedCrossRef Quesada PR, Esteban LL, Garcia JR, Sanchez RV, Garcia TM, Alonso-Vega GG, et al. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. Int J Clin Pharm. 2015;37(5):865–72.PubMedCrossRef
39.
go back to reference Estrella MM, Li M, Tin A, Abraham AG, Shlipak MG, Penugonda S, et al. The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status. Clin Infect Dis. 2015;60(4):646–52.PubMedCrossRef Estrella MM, Li M, Tin A, Abraham AG, Shlipak MG, Penugonda S, et al. The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status. Clin Infect Dis. 2015;60(4):646–52.PubMedCrossRef
40.
go back to reference Lapadula G, Bernasconi DP, Casari S, Maggiolo F, Cauda R, Di Pietro M, et al. Risk of chronic kidney disease among patients developing mild renal impairment during Tenofovir-containing antiretroviral treatment. PLoS ONE [Electronic Resource]. 2016;11(9):e0162320.CrossRef Lapadula G, Bernasconi DP, Casari S, Maggiolo F, Cauda R, Di Pietro M, et al. Risk of chronic kidney disease among patients developing mild renal impairment during Tenofovir-containing antiretroviral treatment. PLoS ONE [Electronic Resource]. 2016;11(9):e0162320.CrossRef
41.
go back to reference Nishijima T, Kurosawa T, Tanaka N, Kawasaki Y, Kikuchi Y, Oka S, et al. Urinary beta2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy. AIDS. 2016;30(10):1563–71.PubMedCrossRef Nishijima T, Kurosawa T, Tanaka N, Kawasaki Y, Kikuchi Y, Oka S, et al. Urinary beta2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy. AIDS. 2016;30(10):1563–71.PubMedCrossRef
42.
go back to reference Hara M, Yanagisawa N, Ohta A, Momoki K, Tsuchiya K, Nitta K, et al. Increased non-HDL-C level linked with a rapid rate of renal function decline in HIV-infected patients. Clin Exp Nephrol. 2017;21(2):275–82.PubMedCrossRef Hara M, Yanagisawa N, Ohta A, Momoki K, Tsuchiya K, Nitta K, et al. Increased non-HDL-C level linked with a rapid rate of renal function decline in HIV-infected patients. Clin Exp Nephrol. 2017;21(2):275–82.PubMedCrossRef
43.
go back to reference De Waal R, Cohen K, Fox MP, Stinson K, Maartens G, Boulle A, et al. Changes in estimated glomerular filtration rate over time in south African HIV-1-infected patients receiving tenofovir: a retrospective cohort study. J Int AIDS Soc. 2017;20(1):21317.PubMedPubMedCentralCrossRef De Waal R, Cohen K, Fox MP, Stinson K, Maartens G, Boulle A, et al. Changes in estimated glomerular filtration rate over time in south African HIV-1-infected patients receiving tenofovir: a retrospective cohort study. J Int AIDS Soc. 2017;20(1):21317.PubMedPubMedCentralCrossRef
44.
go back to reference Rossi C, Raboud J, Walmsley S, Cooper C, Antoniou T, Burchell AN, et al. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. BMC Infect Dis. 2017;17(1):246.PubMedPubMedCentralCrossRef Rossi C, Raboud J, Walmsley S, Cooper C, Antoniou T, Burchell AN, et al. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. BMC Infect Dis. 2017;17(1):246.PubMedPubMedCentralCrossRef
45.
go back to reference Suzuki S, Nishijima T, Kawasaki Y, Kurosawa T, Mutoh Y, Kikuchi Y, et al. Effect of Tenofovir Disoproxil fumarate on incidence of chronic kidney disease and rate of estimated glomerular filtration rate decrement in HIV-1-infected treatment-Naïve Asian patients: results from 12-year observational cohort. AIDS Patient Care STDs. 2017;31(3):105–12.PubMedPubMedCentralCrossRef Suzuki S, Nishijima T, Kawasaki Y, Kurosawa T, Mutoh Y, Kikuchi Y, et al. Effect of Tenofovir Disoproxil fumarate on incidence of chronic kidney disease and rate of estimated glomerular filtration rate decrement in HIV-1-infected treatment-Naïve Asian patients: results from 12-year observational cohort. AIDS Patient Care STDs. 2017;31(3):105–12.PubMedPubMedCentralCrossRef
46.
go back to reference Wong C, Gange SJ, Buchacz K, Moore RD, Justice AC, Horberg MA, et al. First occurrence of diabetes, chronic kidney disease, and hypertension among north American HIV-infected adults, 2000-2013. Clin Infect Dis. 2017;64(4):459–67.PubMed Wong C, Gange SJ, Buchacz K, Moore RD, Justice AC, Horberg MA, et al. First occurrence of diabetes, chronic kidney disease, and hypertension among north American HIV-infected adults, 2000-2013. Clin Infect Dis. 2017;64(4):459–67.PubMed
47.
go back to reference Bouatou Y, Ageron AG, Bernasconi E, Battegay M, Hoffmann M, Staehelin C, et al. Lipodystrophy increases the risk of CKD development in HIV-positive patients in Switzerland: the LIPOKID study. Kidney Int Rep. 2018;3(5):1089–99.PubMedPubMedCentralCrossRef Bouatou Y, Ageron AG, Bernasconi E, Battegay M, Hoffmann M, Staehelin C, et al. Lipodystrophy increases the risk of CKD development in HIV-positive patients in Switzerland: the LIPOKID study. Kidney Int Rep. 2018;3(5):1089–99.PubMedPubMedCentralCrossRef
48.
go back to reference Cheung J, Puhr R, Petoumenos K, Cooper DA, Woolley I, Gunathilake M, et al. Chronic kidney disease in Australian human immunodeficiency virus-infected patients: analysis of the Australian HIV observational database. Nephrology. 2018;23(8):778–86.PubMedCrossRef Cheung J, Puhr R, Petoumenos K, Cooper DA, Woolley I, Gunathilake M, et al. Chronic kidney disease in Australian human immunodeficiency virus-infected patients: analysis of the Australian HIV observational database. Nephrology. 2018;23(8):778–86.PubMedCrossRef
49.
go back to reference Jones R, Hamzah L, Williams D, Winston A, Burns F, Phillips AN, et al. Chronic kidney disease risk in African and Caribbean populations with HIV. J Infect Dis. 2018;218(11):1767–72.PubMedPubMedCentralCrossRef Jones R, Hamzah L, Williams D, Winston A, Burns F, Phillips AN, et al. Chronic kidney disease risk in African and Caribbean populations with HIV. J Infect Dis. 2018;218(11):1767–72.PubMedPubMedCentralCrossRef
50.
go back to reference Joshi K, Boettiger D, Kerr S, Nishijima T, Van Nguyen K, Ly PS, et al. Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia. Pharmacoepidemiol Drug Saf. 2018;27(11):1209–16.PubMedPubMedCentralCrossRef Joshi K, Boettiger D, Kerr S, Nishijima T, Van Nguyen K, Ly PS, et al. Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia. Pharmacoepidemiol Drug Saf. 2018;27(11):1209–16.PubMedPubMedCentralCrossRef
51.
go back to reference Woolnough EL, Hoy JF, Cheng AC, Walker RG, Chrysostomou A, Woolley I, et al. Predictors of chronic kidney disease and utility of risk prediction scores in HIV-positive individuals. AIDS. 2018;32(13):1829–35.PubMedCrossRef Woolnough EL, Hoy JF, Cheng AC, Walker RG, Chrysostomou A, Woolley I, et al. Predictors of chronic kidney disease and utility of risk prediction scores in HIV-positive individuals. AIDS. 2018;32(13):1829–35.PubMedCrossRef
52.
go back to reference Pongpirul W, Pongpirul K, Ananworanich J, Klinbuayaem V, Avihingsanon A, Prasithsirikul W. 【危险因素-DM/高TC/age/VL】chronic kidney disease incidence and survival of Thai HIV-infected patients. AIDS. 2018;32(3):393–8.PubMedCrossRef Pongpirul W, Pongpirul K, Ananworanich J, Klinbuayaem V, Avihingsanon A, Prasithsirikul W. 【危险因素-DM/高TC/age/VL】chronic kidney disease incidence and survival of Thai HIV-infected patients. AIDS. 2018;32(3):393–8.PubMedCrossRef
53.
go back to reference Ojeh BV, Abah IO, Ugoagwu P, Agaba PA, Agbaji OO, Gyang SS. Incidence and predictors of tenofovir disoproxil fumarate-induced renal impairment in HIV infected nigerian patients. Germs. 2018;8(2):67–76.PubMedPubMedCentralCrossRef Ojeh BV, Abah IO, Ugoagwu P, Agaba PA, Agbaji OO, Gyang SS. Incidence and predictors of tenofovir disoproxil fumarate-induced renal impairment in HIV infected nigerian patients. Germs. 2018;8(2):67–76.PubMedPubMedCentralCrossRef
54.
go back to reference Matłosz B, Pietraszkiewicz E, Firląg-Burkacka E, Grycner E, Horban A, Kowalska JD. Risk factors for kidney disease among HIV-1 positive persons in the methadone program. Clin Exp Nephrol. 2019;23(3):342–8.PubMedCrossRef Matłosz B, Pietraszkiewicz E, Firląg-Burkacka E, Grycner E, Horban A, Kowalska JD. Risk factors for kidney disease among HIV-1 positive persons in the methadone program. Clin Exp Nephrol. 2019;23(3):342–8.PubMedCrossRef
55.
go back to reference Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis. 2015;60(4):627–38.PubMedCrossRef Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis. 2015;60(4):627–38.PubMedCrossRef
56.
go back to reference Kabore NF, Poda A, Zoungrana J, Da O, Ciaffi L, Semde A, et al. Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting. BMC Nephrol. 2019;20. Kabore NF, Poda A, Zoungrana J, Da O, Ciaffi L, Semde A, et al. Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting. BMC Nephrol. 2019;20.
57.
go back to reference Domingo P, Suarez-Lozano I, Gutierrez F, Estrada V, Knobel H, Palacios R, et al. Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: results from the VACH longitudinal cohort study. Nefrologia. 2019;39(5):497–505.PubMedCrossRef Domingo P, Suarez-Lozano I, Gutierrez F, Estrada V, Knobel H, Palacios R, et al. Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: results from the VACH longitudinal cohort study. Nefrologia. 2019;39(5):497–505.PubMedCrossRef
58.
go back to reference Eaton EF, Tamhane A, Davy-Mendez T, Moore RD, Mathews WC, Saag MS, et al. Brief report: kidney dysfunction does not contribute significantly to antiretroviral therapy modification in treatment-naive PLWH receiving initial ART. J Acquir Immune Defic Syndr. 2019;81(1):e6–9.PubMedPubMedCentralCrossRef Eaton EF, Tamhane A, Davy-Mendez T, Moore RD, Mathews WC, Saag MS, et al. Brief report: kidney dysfunction does not contribute significantly to antiretroviral therapy modification in treatment-naive PLWH receiving initial ART. J Acquir Immune Defic Syndr. 2019;81(1):e6–9.PubMedPubMedCentralCrossRef
59.
go back to reference Mills AM, Schulman KL, Fusco JS, Brunet L, Hsu R, Beyer A, et al. Validation of the data collection on adverse events of anti-HIV drugs (D:a:D) chronic kidney disease risk score in HIV-infected patients in the USA. HIV Med. 2020;21(5):299–308.PubMedPubMedCentralCrossRef Mills AM, Schulman KL, Fusco JS, Brunet L, Hsu R, Beyer A, et al. Validation of the data collection on adverse events of anti-HIV drugs (D:a:D) chronic kidney disease risk score in HIV-infected patients in the USA. HIV Med. 2020;21(5):299–308.PubMedPubMedCentralCrossRef
60.
go back to reference Han WM, Bijker R, Chandrasekaran E, Pujari S, Ng OT, Ly PS, et al. Validation of the D: a: D chronic kidney disease risk score model among people living with HIV in the Asia-Pacific. J Acquir Immune Defic Syndr. 2020;85(4):489–97.PubMedPubMedCentralCrossRef Han WM, Bijker R, Chandrasekaran E, Pujari S, Ng OT, Ly PS, et al. Validation of the D: a: D chronic kidney disease risk score model among people living with HIV in the Asia-Pacific. J Acquir Immune Defic Syndr. 2020;85(4):489–97.PubMedPubMedCentralCrossRef
61.
go back to reference Medapalli RK, Parikh CR, Gordon K, Brown ST, Butt AA, Gibert CL, et al. Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the veterans aging cohort study. J Acquir Immune Defic Syndr. 2012;60(4):393–9.PubMedPubMedCentralCrossRef Medapalli RK, Parikh CR, Gordon K, Brown ST, Butt AA, Gibert CL, et al. Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the veterans aging cohort study. J Acquir Immune Defic Syndr. 2012;60(4):393–9.PubMedPubMedCentralCrossRef
62.
go back to reference Suzuki S, Nishijima T, Kawasaki Y, Kurosawa T, Mutoh Y, Kikuchi Y, et al. Effect of tenofovir disoproxil fumarate on incidence of chronic kidney disease and rate of estimated glomerular filtration rate decrement in HIV-1-infected treatment-naive Asian patients: results from 12-year observational cohort. AIDS Patient Care STDs. 2017;31(3):105–12.PubMedPubMedCentralCrossRef Suzuki S, Nishijima T, Kawasaki Y, Kurosawa T, Mutoh Y, Kikuchi Y, et al. Effect of tenofovir disoproxil fumarate on incidence of chronic kidney disease and rate of estimated glomerular filtration rate decrement in HIV-1-infected treatment-naive Asian patients: results from 12-year observational cohort. AIDS Patient Care STDs. 2017;31(3):105–12.PubMedPubMedCentralCrossRef
63.
go back to reference Chaisiri K, Bowonwatanuwong C, Kasettratat N, Kiertiburanakul S. Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight. Curr HIV Res. 2010;8(7):504–9.PubMedCrossRef Chaisiri K, Bowonwatanuwong C, Kasettratat N, Kiertiburanakul S. Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight. Curr HIV Res. 2010;8(7):504–9.PubMedCrossRef
64.
go back to reference Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One. 2011;6(7):e22661.PubMedPubMedCentralCrossRef Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One. 2011;6(7):e22661.PubMedPubMedCentralCrossRef
65.
go back to reference Nishijima T, Gatanaga H, Komatsu H, Tsukada K, Shimbo T, Aoki T, et al. Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection. PLoS One. 2012;7(1):e29977.PubMedPubMedCentralCrossRef Nishijima T, Gatanaga H, Komatsu H, Tsukada K, Shimbo T, Aoki T, et al. Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection. PLoS One. 2012;7(1):e29977.PubMedPubMedCentralCrossRef
66.
go back to reference Koh HM, Suresh K. Tenofovir-induced nephrotoxicity: a retrospective cohort study. Med J Malaysia. 2016;71(6):308–12.PubMed Koh HM, Suresh K. Tenofovir-induced nephrotoxicity: a retrospective cohort study. Med J Malaysia. 2016;71(6):308–12.PubMed
67.
go back to reference Lee JE, Lee S, Song SH, Kwak IS, Lee SH. Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea. Korean J Intern Med. 2019;34(2):409–17.PubMedCrossRef Lee JE, Lee S, Song SH, Kwak IS, Lee SH. Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea. Korean J Intern Med. 2019;34(2):409–17.PubMedCrossRef
68.
go back to reference Low JZ, Khoo SP, Nor Azmi N, Chong ML, Sulaiman H, Azwa I, et al. Is the risk of tenofovir-induced nephrotoxicity similar in treatment-naive compared to treatment-experienced patients? J Pharm Pract Res. 2018;48(3):242–50.CrossRef Low JZ, Khoo SP, Nor Azmi N, Chong ML, Sulaiman H, Azwa I, et al. Is the risk of tenofovir-induced nephrotoxicity similar in treatment-naive compared to treatment-experienced patients? J Pharm Pract Res. 2018;48(3):242–50.CrossRef
69.
go back to reference Mocroft A, Ryom L, Oprea C, Li Q, Rauch A, Boesecke C, et al. Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons. AIDS. 2020;34(10):1485–95.PubMedCrossRef Mocroft A, Ryom L, Oprea C, Li Q, Rauch A, Boesecke C, et al. Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons. AIDS. 2020;34(10):1485–95.PubMedCrossRef
70.
go back to reference Sutton SS, Magagnoli J, Hardin JW, Hsu LI, Beaubrun A, Majethia S, et al. Association of tenofovir disoproxil fumarate exposure with chronic kidney disease and osteoporotic fracture in US veterans with HIV. Curr Med Res Opin. 2020;36(10):1635–42.PubMedCrossRef Sutton SS, Magagnoli J, Hardin JW, Hsu LI, Beaubrun A, Majethia S, et al. Association of tenofovir disoproxil fumarate exposure with chronic kidney disease and osteoporotic fracture in US veterans with HIV. Curr Med Res Opin. 2020;36(10):1635–42.PubMedCrossRef
71.
go back to reference Tan Q, He YH, Yang TT, Yan DM, Wang Y, Zhao X, et al. Effects of long-term exposure to tenofovir disoproxil fumarate-containing antiretroviral therapy on renal function in HIV-positive Chinese patients. J Microbiol Immunol Infect. 2019;52(5):710–9.PubMedCrossRef Tan Q, He YH, Yang TT, Yan DM, Wang Y, Zhao X, et al. Effects of long-term exposure to tenofovir disoproxil fumarate-containing antiretroviral therapy on renal function in HIV-positive Chinese patients. J Microbiol Immunol Infect. 2019;52(5):710–9.PubMedCrossRef
72.
go back to reference Alves TP, Hulgan T, Wu P, Sterling TR, Stinnette SE, Rebeiro PF, et al. Race, kidney disease progression, and mortality risk in HIV-infected persons. Clin J Am Soc Nephrol. 2010;5(12):2269–75.PubMedPubMedCentralCrossRef Alves TP, Hulgan T, Wu P, Sterling TR, Stinnette SE, Rebeiro PF, et al. Race, kidney disease progression, and mortality risk in HIV-infected persons. Clin J Am Soc Nephrol. 2010;5(12):2269–75.PubMedPubMedCentralCrossRef
73.
go back to reference Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010;53(1):62–9.PubMedCrossRef Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010;53(1):62–9.PubMedCrossRef
74.
go back to reference Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K. A simple model for predicting incidence of chronic kidney disease in HIV-infected patients. Clin Exp Nephrol. 2011;15(2):242–7.PubMedCrossRef Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K. A simple model for predicting incidence of chronic kidney disease in HIV-infected patients. Clin Exp Nephrol. 2011;15(2):242–7.PubMedCrossRef
75.
go back to reference Tordato F, Cozzi Lepri A, Cicconi P, De Luca A, Antinori A, Colangeli V, et al. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med. 2011;12(1):4–13.PubMedCrossRef Tordato F, Cozzi Lepri A, Cicconi P, De Luca A, Antinori A, Colangeli V, et al. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med. 2011;12(1):4–13.PubMedCrossRef
76.
go back to reference Dietrich LG, Thorball CW, Ryom L, Burkhalter F, Hasse B, Thurnheer MC, et al. Rapid Progression of Kidney Dysfunction in Swiss People Living with HIV: Contribution of Polygenic Risk Score and D:A:D Clinical Risk Score. J Infect Dis. 2020;05. Dietrich LG, Thorball CW, Ryom L, Burkhalter F, Hasse B, Thurnheer MC, et al. Rapid Progression of Kidney Dysfunction in Swiss People Living with HIV: Contribution of Polygenic Risk Score and D:A:D Clinical Risk Score. J Infect Dis. 2020;05.
77.
go back to reference Kalemeera F, Godman B, Stergachis A, Rennie T. Tenofovir disoproxil fumarate associated nephrotoxicity: a retrospective cohort study at two referral hospitals in Namibia. Pharmacoepidemiol Drug Saf. 2021;30(2):189–200.PubMedCrossRef Kalemeera F, Godman B, Stergachis A, Rennie T. Tenofovir disoproxil fumarate associated nephrotoxicity: a retrospective cohort study at two referral hospitals in Namibia. Pharmacoepidemiol Drug Saf. 2021;30(2):189–200.PubMedCrossRef
78.
go back to reference Kamkuemah M, Kaplan R, Bekker LG, Little F, Myer L. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a primary healthcare setting in South Africa. Tropical Med Int Health. 2015;20(4):518–26.CrossRef Kamkuemah M, Kaplan R, Bekker LG, Little F, Myer L. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a primary healthcare setting in South Africa. Tropical Med Int Health. 2015;20(4):518–26.CrossRef
79.
go back to reference Sonoda H, Nakamura K, Tamakoshi A. Ankle-brachial index is a predictor of future incident chronic kidney disease in a general Japanese population. J Atheroscler Thromb. 2019;26(12):1054–61.PubMedPubMedCentralCrossRef Sonoda H, Nakamura K, Tamakoshi A. Ankle-brachial index is a predictor of future incident chronic kidney disease in a general Japanese population. J Atheroscler Thromb. 2019;26(12):1054–61.PubMedPubMedCentralCrossRef
80.
go back to reference Jespersen NA, Axelsen F, Dollerup J, Nørgaard M, Larsen CS. The burden of non-communicable diseases and mortality in people living with HIV (PLHIV) in the pre-, early- and late-HAART era. HIV Med. 2021;22(6):478–90.PubMedPubMedCentralCrossRef Jespersen NA, Axelsen F, Dollerup J, Nørgaard M, Larsen CS. The burden of non-communicable diseases and mortality in people living with HIV (PLHIV) in the pre-, early- and late-HAART era. HIV Med. 2021;22(6):478–90.PubMedPubMedCentralCrossRef
81.
go back to reference Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute Dialysis quality initiative (ADQI) group. Crit Care. 2004;8(4):R204–12.PubMedPubMedCentralCrossRef Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute Dialysis quality initiative (ADQI) group. Crit Care. 2004;8(4):R204–12.PubMedPubMedCentralCrossRef
82.
go back to reference He L, Wei Q, Liu J, Yi M, Liu Y, Liu H, et al. AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int. 2017;92(5):1071–83.PubMedPubMedCentralCrossRef He L, Wei Q, Liu J, Yi M, Liu Y, Liu H, et al. AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int. 2017;92(5):1071–83.PubMedPubMedCentralCrossRef
83.
go back to reference Wikman P, Safont P, Del Palacio M, Moreno A, Moreno S, Casado JL. The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients. Nephrol Dial Transplant. 2013;28(8):2073–81.PubMedCrossRef Wikman P, Safont P, Del Palacio M, Moreno A, Moreno S, Casado JL. The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients. Nephrol Dial Transplant. 2013;28(8):2073–81.PubMedCrossRef
84.
go back to reference Jose S, Nelson M, Phillips A, Chadwick D, Trevelion R, Jones R, et al. Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir. AIDS. 2017;31(4):485–92.PubMedCrossRef Jose S, Nelson M, Phillips A, Chadwick D, Trevelion R, Jones R, et al. Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir. AIDS. 2017;31(4):485–92.PubMedCrossRef
85.
go back to reference De Beaudrap P, Diallo MB, Landman R, Gueye NF, Ndiaye I, Diouf A, et al. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215). AIDS Res Hum Retrovir. 2010;26(11):1221–7.PubMedCrossRef De Beaudrap P, Diallo MB, Landman R, Gueye NF, Ndiaye I, Diouf A, et al. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215). AIDS Res Hum Retrovir. 2010;26(11):1221–7.PubMedCrossRef
86.
go back to reference Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311(24):2518–31.PubMedPubMedCentralCrossRef Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311(24):2518–31.PubMedPubMedCentralCrossRef
Metadata
Title
Incidence of impaired kidney function among people with HIV: a systematic review and meta-analysis
Authors
Ruizi Shi
Xiaoxiao Chen
Haijiang Lin
Yingying Ding
Na He
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02721-x

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue